Page 403 - Binder2

now, edible biologics challenge the very foundation of that
logic.

Edible Biologics Collapse the Scarcity Myth

What happens when a life-saving therapy can be:

• Grown in a plant instead of synthesized in a
bioreactor?
• Freeze-dried and mailed, with no refrigeration or
clinic visit required?
• Produced locally using open-source genetic
constructs and modular growth pods?

Suddenly, the infrastructure that once justified high costs
begins to look like what it truly is: a legacy system of
control.

And with that unraveling comes a critical question:

What does ethical distribution look like in a world
where biologics are no longer inherently rare?

A Different Moral Contract

In the legacy model, ethics were shaped by constraint: “We
only have so much drug. We must triage.” This fostered a
framework of justified exclusion—where payers,
regulators, and manufacturers decided who qualified, who
waited, and who was out of luck.

401